当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mutation Burden Predicts Anti–PD-1 Response
Cancer Discovery ( IF 28.2 ) Pub Date : 2018-03-01 , DOI: 10.1158/2159-8290.cd-nb2018-005
American Association for Cancer Research

A new study finds that objective response rates to anti–PD-1 therapies correlate with tumor mutation burden for most of the 27 cancer types studied. Objective response rates were higher than expected for Merkel cell carcinoma and renal cell carcinoma, which may be particularly immunogenic. The objective response rate was unexpectedly low for colorectal cancer with mismatch repair proficiency.



中文翻译:

突变负担预测抗PD-1反应

一项新研究发现,对于所研究的27种癌症中的大多数,抗PD-1治疗的客观反应率与肿瘤突变负担相关。客观反应率高于默克尔细胞癌和肾细胞癌的预期反应率,这可能是特别具有免疫原性的。具有错配修复能力的大肠癌的客观应答率出乎意料地低。

更新日期:2018-03-02
down
wechat
bug